Cargando…

Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis

OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Ka...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingre, Caroline, Chen, Lin, Zhan, Yiqiang, Termorshuizen, Jet, Yin, Li, Fang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274849/
https://www.ncbi.nlm.nih.gov/pubmed/32221024
http://dx.doi.org/10.1212/WNL.0000000000009322
_version_ 1783542672609247232
author Ingre, Caroline
Chen, Lin
Zhan, Yiqiang
Termorshuizen, Jet
Yin, Li
Fang, Fang
author_facet Ingre, Caroline
Chen, Lin
Zhan, Yiqiang
Termorshuizen, Jet
Yin, Li
Fang, Fang
author_sort Ingre, Caroline
collection PubMed
description OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. METHODS: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. RESULTS: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. CONCLUSIONS: Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis.
format Online
Article
Text
id pubmed-7274849
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-72748492020-06-23 Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis Ingre, Caroline Chen, Lin Zhan, Yiqiang Termorshuizen, Jet Yin, Li Fang, Fang Neurology Article OBJECTIVE: To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden. METHODS: Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised score, and progression rate. RESULTS: A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41–0.89, p = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44–0.92, p = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46–0.92, p = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44–0.88, p = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43–0.86, p < 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables. CONCLUSIONS: Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis. Lippincott Williams & Wilkins 2020-04-28 /pmc/articles/PMC7274849/ /pubmed/32221024 http://dx.doi.org/10.1212/WNL.0000000000009322 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Ingre, Caroline
Chen, Lin
Zhan, Yiqiang
Termorshuizen, Jet
Yin, Li
Fang, Fang
Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title_full Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title_fullStr Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title_full_unstemmed Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title_short Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
title_sort lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274849/
https://www.ncbi.nlm.nih.gov/pubmed/32221024
http://dx.doi.org/10.1212/WNL.0000000000009322
work_keys_str_mv AT ingrecaroline lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis
AT chenlin lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis
AT zhanyiqiang lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis
AT termorshuizenjet lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis
AT yinli lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis
AT fangfang lipidsapolipoproteinsandprognosisofamyotrophiclateralsclerosis